Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies — Kenneth B. Gordon (2017) | RDL Network
Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies
Article 2017 en
Authors
KG
Kenneth B. Gordon
AB
Andrew Blauvelt
PF
Peter Foley
Abstract
1 min read
This analysis demonstrates a high degree of efficacy with guselkumab treatment compared with placebo at week 16 and with adalimumab at week 24 among broad subpopulations of patients with varying baseline demographics, disease characteristics and previous psoriasis treatments.
April W. Armstrong, Kilian Eyerich, Curdin Conrad, Yihong Zhu, Ya‐Wen Yang, Megan Miller, Yin You, Yaung‐Kaung Shen, Peter Foley, Christopher Em Griffiths, Bruce Strober
Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, Carolin Daamen, Christopher Em Griffiths
Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.